

-2-

A1
canceled

amount of a composition comprising a recombinant poliovirus nucleic acid having a foreign nucleotide sequence encoding, in an expressible form, a protein or fragment thereof substituted for at least a portion of the P1 capsid precursor region of the poliovirus genome.

A2

38. (Amended) The method of claim 35 wherein the protein or fragment thereof is selected from the group consisting of a secretory protein, a cell surface protein, and a structural protein.

39. (Amended) The method of claim 38 wherein the secretory protein is selected from the group consisting of interleukin, cytokine, and factor.

A3

45. (Amended) A method for delivering a protein, or fragment thereof, to a subject, comprising the steps of:

- (a) removing host cells from the subject; and
- (b) contacting the host cells with
 - (i) a recombinant poliovirus nucleic acid having a foreign nucleotide sequence substituted for at least a portion of the P1 capsid precursor region of the poliovirus genome; and
 - (ii) an expression vector lacking an infectious poliovirus genome, the nucleic acid of which encodes poliovirus P1 capsid precursor protein and directs expression of the P1 capsid precursor protein; and
- (c) maintaining the cultured host cells under conditions appropriate for introduction of the recombinant poliovirus nucleic acid and the expression vector into the host cells, thereby generating modified host cells which express a foreign protein or fragment thereof encoded by the foreign nucleotide sequence; and
- (d) reintroducing the modified host cells into the subject.

Please add new claims 46-63 as follows:

A4

46. (New) The method of claim 45 wherein the recombinant poliovirus nucleic acid is encapsidated.

A4
cont'd

47. (New) The method of claim 45 wherein the protein or fragment thereof is selected from the group consisting of a secretory protein, a cell surface protein, and a structural protein.

48. (New) The method of claim 47 wherein the secretory protein is selected from the group consisting of interleukin, cytokine, and factor.

49. (New) A method for expressing a foreign gene in a cell comprising:
contacting the cell, in a physiologically acceptable carrier, with an effective amount of a composition comprising a recombinant poliovirus nucleic acid having a foreign nucleotide sequence encoding, in an expressible form, a gene product substituted for at least a portion of the P1 capsid precursor region of the poliovirus genome,
under conditions appropriate for introduction of the recombinant poliovirus nucleic acid into the cell, thereby generating a modified cell which expresses a foreign gene product encoded by the foreign nucleotide sequence.

50. (New) The method of claim 49 wherein the recombinant poliovirus nucleic acid is encapsidated.

51. (New) The method of claim 49 wherein the cell is in a subject.

52. (New) The method of claim 51 wherein the cell is contacted ex vivo and the modified cell is then reintroduced into the subject.

53. (New) The method of claim 49 wherein the cell is selected from the group consisting of a peripheral blood mononuclear cell, a B cell, a T cell, a monocyte, a macrophage, a cutaneous cell, a muscle cell, a kidney cell, a mucosal cell, and a tumor cell.

54. (New) The method of claim 52 wherein the cell is reintroduced into the subject by injection or implantation.

-4-

A4
canceled

55. (New) The method of claim 49 wherein the foreign gene encodes a gene product selected from the group consisting of a protein or fragment thereof, an antisense gene, and a ribozyme.

56. (New) The method of claim 55 wherein the protein is a therapeutic protein.

57. (New) The method of claim 55 wherein the protein or fragment thereof is selected from the group consisting of a secretory protein, a cell surface protein, and a structural protein.

58. (New) The method of claim 56 wherein the secretory protein is selected from the group consisting of an interleukin, a cytokine, and a factor.

59. (New) The method of claim 58 wherein the interleukin is selected from the group consisting of IL-1, IL-2, and IL-6.

60. (New) The method of claim 58 wherein the cytokine is selected from the group consisting of GM-CSF, and interferon- γ .

61. (New) The method of claim 55 wherein the antisense gene corresponds to a gene selected from the group consisting of a viral gene and an oncogene.

62. (New) The method of claim 60 wherein the viral gene is an HIV gene.

63. (New) The method of claim 55 wherein the ribozyme comprises an activity selected from the group consisting of endonuclease activity and polymerase activity.

REMARKS

Claims 1-45 were pending in the application. Claims 1-34 and 40-44 have been canceled without prejudice or disclaimer, claims 35, 38, 39 and 45 have been amended, and new claims 46-63 have been added. Accordingly, claims 35-39 and 45-63 will be pending in the application upon entry of the amendments presented herein.

Support for amended claims 35, 38, 39, and 45, and new claims 46-63, may be found throughout the specification and claims as originally filed. In particular, support